Novo Nordisk receives FDA warning regarding US inspection in 2025

Core Viewpoint - Novo Nordisk received a warning letter from the U.S. Food and Drug Administration (FDA) regarding an inspection at its Plainsboro site in early 2025, but the company is confident in resolving the issues without impacting production or forecasts [1]. Company Summary - The warning letter was issued following an inspection conducted by the FDA at Novo Nordisk's facility in Plainsboro, New Jersey [1]. - The company has initiated a corrective and preventative action plan and is keeping the FDA informed about its progress [1]. - Novo Nordisk does not anticipate any negative effects on its production or previously shared forecasts as a result of this warning [1].